<DOC>
	<DOCNO>NCT00430001</DOCNO>
	<brief_summary>In open-label randomised phase III-trial patient metastatic HER2-positive breast cancer naive chemotherapy normal organ function WHO performance status &lt; 3 randomise receive either docetaxel 100 mg/m2 i.v . plus trastuzumab 6 mg/kg ( 8 mg/kg load dose ) q 3 week vinorelbine 30 35 mg/m2 day 1+8 plus trastuzumab 6 mg/kg ( 8 mg/kg load dose ) q 3 week . Primary endpoint time progression . Secondary endpoint include overall survival , time treatment failure , response rate , duration response toxicity . The study hypothesis docetaxel efficient vinorelbine also toxic .</brief_summary>
	<brief_title>Vinorelbine Plus ( + ) Trastuzumab v Docetaxel Plus ( + ) Trastuzumab 1 Line Treatment HER2 Positive ( + ) Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Locally advanced metastatic HER2positive breast cancer WHO performance status &lt; 3 Chemotherapy metastatic breast cancer adjuvant therapy within 12 month docetaxel , vinorelbine trastuzumab Severe dyspnoea Abnormal organ function include cardiac</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Metastatic breast neoplasm</keyword>
</DOC>